Financing ·
BlossomHill Therapeutics, Inc. completed its initial public offering on August 10, 2026, selling 9,375,000 shares of…
BLSMBlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc. completed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The transaction generated approximately $150.0 million in aggregate gross proceeds before deducting underwriting discounts and offering expenses. Concurrently, the company filed an amended and restated certificate of incorporation and adopted new bylaws effective immediately prior to the IPO closing. BlossomHill Therapeutics operates in the biotechnology industry, focusing on the discovery and development of therapeutic treatments.